BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Liver cancer In vitro , cell culture and mouse studies identified a SALL4-derived peptide inhibitor of the SALL4-RBBP4 interaction that could help treat hepatocellular carcinoma (HCC). Chemical synthesis and in vitro testing of analogs of...
BioCentury | Apr 10, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy CRISPR-based gene editing with an engineered Cas9-based fusion protein that enhances homology-dependent repair (HDR) could enable greater integration of therapeutic genes than standard Cas9. The system utilizes an engineered enzyme consisting of...
BioCentury | Mar 10, 2017
Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
BioCentury | Sep 26, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction Retinoblastoma binding protein 4 (RBBP4; RBAP48) Studies in patient samples and mice suggest increasing RBAP48 levels could help treat...
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Aneurysm Cyclin M2 (CNNM2); retinoblastoma binding protein 8 (RBBP8); StAR-related lipid transfer domain containing 13 (STARD13) A genomewide association study identified three SNPs that could...
BioCentury | Apr 16, 2009
Cover Story

Probing the character of proteins

...Using fluopol-ABPP, the team screened libraries against two uncharacterized proteins implicated in human cancers: retinoblastoma binding protein 9 (RBBP9...
...and glutathione S -transferase w1 ( GSTO1 ). A screen of a 19,000-member library against RBBP9...
...results of both screens. Next, the team screened emetine and 75 structurally similar compounds against RBBP9...
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Sjögren's syndrome Retinoblastoma binding protein 4 (RBBP4; RBAP48) A study in mice suggests that inhibiting RBAP48 may help treat or prevent...
Items per page:
1 - 7 of 7